
==== Front
RSC Adv
RSC Adv
RA
RSCACL
RSC Advances
2046-2069
The Royal Society of Chemistry

d4ra03356f
10.1039/d4ra03356f
Chemistry
Synthesis, kinetics, mechanisms, and bioactivity evaluations of a novel Zn(ii) complex
Dey Anwesha a†
https://orcid.org/0000-0002-7150-4404
Kumar Ramesh b†
https://orcid.org/0000-0003-1694-0366
Dutta Bhramar c
Bandopadhyay Rajib c
https://orcid.org/0000-0001-7719-8586
Chakrabortty Sankha d
https://orcid.org/0000-0002-0548-8581
Khan Moonis Ali e
Saratale Rijuta Ganesh f
Saratale Ganesh Dattatraya g
https://orcid.org/0000-0002-5478-765X
Jeon Byong Hun b
https://orcid.org/0000-0003-0540-287X
Ghosh Alak K. a
a Department of Chemistry, The University of Burdwan Burdwan (E) 713104 West Bengal India akghosh@chem.buruniv.ac.in

b Department of Earth Resources & Environmental, Engineering, Hanyang University 222-Wangsimni-ro, Seongdong-gu Seoul 04763 Republic of Korea bhjeon@hanyang.ac.kr

c Department of Botany, The University of Burdwan Burdwan (E) 713104 West Bengal India
d School of Chemical Engineering, Kalinga Institute of Industrial Technology Bhubaneswar 751024 Odisha India
e Chemistry Department, College of Science, King Saud University Riyadh 11451 Saudi Arabia
f Research Institute of Integrative Life Sciences, Dongguk University-Seoul Ilsandong-gu Goyang-si Gyeonggido 10326 Republic of Korea
g Department of Food Science and Biotechnology, Dongguk University-Seoul 32 Dongguk-ro, Ilsandong-gu Goyang-si 10326 Gyeonggi-do Republic of Korea
† These authors contributed equally.

10 9 2024
4 9 2024
10 9 2024
14 39 2869328702
7 5 2024
30 8 2024
This journal is © The Royal Society of Chemistry
2024
The Royal Society of Chemistry
https://creativecommons.org/licenses/by-nc/3.0/ This article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.
Zn(ii)-based anticancer drugs can be suitable alternatives to conventional Pt(ii)-based drugs because of the unique chemical properties of Zn(ii) and low toxicity. In this study, a new hexadentate and heteroleptic Zn(ii) complex ([Zn(bpy)2(OAc)2], 1) was prepared with a conventional N,N-donor ligand (2,2′-bipyridine) and a leaving group (OAc) and characterized via ESI-MS, UV-Vis, and FT-IR spectroscopy. Kinetic and mechanistic investigations of 1 were performed using two biologically relevant ligands (dl-penicillamine and l-cysteine) to understand its selectivity and reactivity. Substitution reactions were determined to be two-step processes in the associative activation mode. Bioactivity studies of 1 revealed moderate to strong DNA-binding, cleaving ability, and antimicrobial properties.

Zn(ii)-based anticancer drugs can be suitable alternatives to conventional Pt(ii)-based drugs because of the unique chemical properties of Zn(ii) and low toxicity.

National Research Foundation of Korea 10.13039/501100003725 2021R1I1A1A01060846 Ministry of Science and ICT, South Korea 10.13039/501100014188 RS-2023-00219983 King Saud University 10.13039/501100002383 RSP2024R345 pubstatusPaginated Article
==== Body
pmcIntroduction

Transition metal complexes are being explored as alternative antitumor agents to Pt(ii) complexes, owing to their lower toxicity and higher efficacy compared to that of the latter.1 In particular, Ru(iii), Ga, and As complexes have emerged as promising anticancer drugs.2 Some Zn(ii) coordination complexes also showed promising DNA binding ability and antitumor activity.3,4 This is attributed to their unique chemical properties, diverse biological functionality, and lower toxicity at even higher doses compared to other metals,5,6 negligible side effects compared to the available anticancer drugs,7 and affordability.

Zn has three unique chemical properties: (i) it has a 3d10 electronic configuration in the +2 state; thus, the Zn(ii) coordination complexes have no ligand-field stabilization energy.8 Hence, they do not have preferential geometry and can form readily exchangeable, flexible, but strong complexes with organic ligands;9 (ii) Zn(ii) has a filled 3d orbital and is thus redox inactive. Hence, they are highly stable in biological reactions and can easily enter biological systems without causing oxidative stress-mediated damage; and (iii) Zn(ii) is classified as a borderline metal ion by Pearson in 1963.10 Therefore, it does not have preference among N, O, or S for coordination. In addition, Zn is an essential trace element and the second-most abundant element in the body.11 It is crucial for all forms of life on the planet. Zn is present in all body fluids and tissues, with maximum fractions in the muscle tissue, skeleton, and liver.12 It has diverse biological functions owing to its redox-inactive nature. Zn(ii) complexes strengthen the immune system;13 regulate RNA transcription and DNA synthesis;14 heal wounds;15,16 maintain cell growth, cell division, differentiation, proliferation,17 and prostaglandin function;14 regulate body fluid pH; enhance collagen formation in hair, nails, and skin;18 and improve memory and mental health.

The physicochemical properties of Zn(ii), such as its diamagnetism, strong Lewis acidity, and d10 configuration, enable the formation of different coordination geometries with chelating ligands of diverse donor atoms and hapticity.3 Moreover, Zn(ii) complexes have exhibited antiproliferative activity, fast ligand exchange, Lewis acid activation, and catalytic activities in hydrolysis and DNA cleavage.19,20 In addition, they are non-toxic, even at high dosages. They have a preventative effect on infectious diseases and are less harmful anticancer drugs.21 In particular, zinc phthalocyanines serve as photosensitizers or light-sensitive compounds during the photodynamic treatment of tumor cells by producing reactive oxygen species (ROS).22 Moreover, Zn(ii) forms dimeric and polymeric complexes with various donor atoms, such as N, O, and S, in ligands of different capacities, resulting in complexes of different geometries and coordination. In particular, Zn(ii) complexes with N-donor ligands have been extensively explored as anticancer agents.3

To further explore the anticancer activity of Zn(ii) complexes with N-donor ligands, in this study, we synthesized a six-coordinated Zn(ii) complex bearing two N-donor ligands (2,2′-bipyridine; bpy) and two acetate groups and explored its kinetics and anticancer mechanistic aspects. The DNA binding ability, cleaving capacity, and germicidal activity of the Zn(ii) complex were evaluated via several bioassays. The aromatic ligand bpy serves as a spectator ligand and facilitates a similar donor environment to that of cis-diamminedichloroplatinum(ii).23

Materials and methods

Chemicals

All chemicals were reagent-grade and used without further purification. Chemicals, such as Zn(OAc)2, dl-penicillamine, l-cysteine, Tris buffer, pBR322, EtBr, and bpy were purchased from Sisco Research Laboratories Pvt. Ltd (India). Calf thymus DNA (ctDNA) and AgClO4 were purchased from Sigma-Aldrich (USA). Ampicillin and potato-dextrose agar were purchased from Hi-Media (USA). A constant ionic strength was maintained using a NaClO4 (0.1 M) solution, and the pH of all the solutions used for the kinetics experiments was adjusted using 1 M NaOH/HClO4 prior to the experiments.

Analytical determination

A Shimadzu UV-vis spectrophotometer (Model UV-3600, Japan) was used for spectroscopic scanning. A Hi-Tech stopped-flow spectrophotometer (Model-TB 85) was used to obtain kinetic data at a controlled temperature. A Shimadzu IR Prestige-21 spectrophotometer (Japan) was used to collect FT-IR data. Mass spectra were obtained using ESI-MS equipment (Waters, Model-Xevo G2-XS QTof, USA) in a positive ion mode. A fluorometer (PerkinElmer, Model-L555 USA) was used to monitor fluorescence quenching. Plasmid DNA (pBR322) treated with [Zn(bpy)2(OAc)2] (1) was analyzed by agarose gel electrophoresis (Bio-Rad, USA).

Synthesis of 1

Complex 1 was prepared by mixing the aqueous solutions of Zn(OAc)2 and bpy in a 1 : 2 molar ratio. Aqueous solutions were prepared using double-distilled water. The solution of bpy was added to the solution of Zn(OAc)2 dropwise with continuous stirring using a magnetic stirrer for 8 h at 27 °C. The precipitated white solid was filtered and washed three times with distilled water.

Kinetics evaluation

The reactions of 1 with dl-penicillamine (L1) and l-cysteine (L2) followed pseudo-first-order kinetics at three different concentrations of ligands and four different temperatures at a physiological pH of 7.4. As the reaction progressed, the maximum difference in the absorbances of 1 and the substituted products 2 (product of L1 and 1) and 3 (product of L2 and 1) were observed at 300 nm (Fig. 1).

Fig. 1 UV-Vis spectra of [Zn(bpy)2(OAc)2] (1), dl-penicillamine (L1)-substituted product (2), and l-cysteine (L2)-substituted product (3). The concentrations of 1 and ligands were 2.0 × 10−4 and 4.0 × 10−3 mol L−1, respectively, and the path length of the quartz cell was 1 cm.

Hence, we monitored the reaction kinetics at 300 nm using five different concentrations (2.0–4.0 × 103 mol L−1) of L1 and L2 and four different temperatures (20–35 °C).

Job's method

To determine the effect of continuous variation in the metal: ligand ratio in 2 and 3 and to obtain a bell-shaped curve, we used Job's method.24,25 Complex 1 and the ligands (L1 and L2) were mixed in an equimolar ratio of 2.0 × 10−4 mol L−1, and the pH of the solution was maintained at 7.4 at room temperature. The vessel was fitted with a reflux condenser to prevent solvent loss due to evaporation while heating the reaction mixture in a 60 °C water bath.

Bioassays

Reaction of 1 with ctDNA

The electronic absorption titration of 1 with ctDNA was conducted in Tris–HCl buffer (pH 7.4); a fixed concentration (0.1 mM) of 1 was titrated against 0–20 μM ctDNA.26 The absorption spectra were recorded every 5 min. The binding constant (Kb) was determined using the following equation:27,281

where εa, εf, and εb are the extinction coefficients of Aobsd/[1], free 1, and the fully bonded complex of 1 with ctDNA, respectively. The slope to the intercept (Kb) was calculated using the [DNA]/(εb − εf) vs. [DNA] plot.29

Fluorescence quenching experiment

EtBr is a fluorescence tag that exhibits intense fluorescence upon intercalation with adjacent base pairs of ctDNA. Hence, it was used to evaluate the binding of 1 and ctDNA.26 The concentration of 1 was increased from 0 to 100 μM in Tris–HCl buffer (pH 7.4) at fixed EtBr and ctDNA concentrations (17 μM). Next, the fluorescence intensities of different solutions were measured at varying ctDNA concentrations. The emission spectra (420–490 nm) of 1, EtBr, and the DNA solution were measured to determine the quenching constant (Ksv) at an excitation wavelength of 375 nm. The Ksv value was determined using the Stern–Volmer equation as follows:2

where I0 and I are the fluorescence intensities of EtBr–DNA and EtBr–DNA–1, respectively, and [Q] is the quencher (1) concentration.30 Furthermore, Kapp, KF, and n are the apparent binding constant, fluorescence binding constant, and total number of binding sites per nucleotide, respectively, which were calculated using eqn (3) and (4).283 KEtBr[EtBr] = Kapp[Q]

4 log(F0 − F)/F = log KF + n log[Q]

where [Q] is the quencher concentration at half the fluorescence intensity of EtBr–DNA, KEtBr = 1.0 × 107 M−1, and [EtBr] = 10 μM.

Plasmid DNA cleavage using 1

Gel electrophoresis was used to monitor plasmid DNA (pBR 322) cleavage by 1. Briefly, an aliquot of 150 ng of plasmid DNA solution in 40 mM Tris-acetate buffer (pH 7.2) was reacted with different concentrations of 1. The final reaction volume was 20 μL. The reaction solution was incubated at 37 °C for 1 h. The sample loading buffer, comprising 0.05% bromophenol blue, 5% glycerol, and 5 μL of 2 mM H4ETDA solution (pH 8.0), the sample (DNA + 1), and 5 μL EtBr were added to 0.8% agarose gel. Agarose gel electrophoresis was performed at ambient temperature and a voltage of 50 mV for 4 h in the dark.31

Antimicrobial assay

The disk diffusion method was employed to investigate the in vitro antimicrobial activities of the ligand (bpy) and 1.32 The in vitro antimicrobial activities of 1 were tested against the fungus Aspergillus niger (MCC1819); Gram-negative bacteria Enterobacter asburiae (GenBank ID MN081607.1) and Escherichia coli (NCIM 1056); and Gram-positive bacteria Staphylococcus aureus (ATCC 29213), Bacillus siamensis (GenBank ID MN134497), Salinicoccus roseus (GenBank ID MN080417), and Halomonas denitrificans (GenBank ID MN080415).33,34 Briefly, 100 μL of 106 conidia per mL suspension culture of Aspergillus niger was spread over potato dextrose agar plates. In addition, the bacterial inoculum was taken from a 24 h-old culture, adjusted to a concentration of 106 CFU mL−1, and spread on Müller–Hinton agar plates using a sterile cotton swab. An agar plate or cylinder was aseptically punched using a sterile cork borer. Freshly prepared solutions of 1 and bpy at desired concentrations (25 μL) were added into the well. The agar plates were then incubated at 37 °C for 24 h. A plate with ampicillin (10 μg per disc) was used as the control. The diameter of the inhibition zone (mm) was measured after incubation. Experiments were repeated in triplicate, and the average values were considered.

Results and discussion

Characterization of 2 and 3

Products 2 and 3 were characterized via Job's method, FT-IR spectroscopy, and ESI-MS. Job's method revealed the metal : ligand ratio (1 : L1 and 1 : L2) in 2 and 3 to be 1 : 2 (Fig. 2). Fig. 3(a)–(c) show the FT-IR spectra of 1, 2, and 3. The spectrum of 1 exhibited bands at 636.79 and 601.88 cm−1 corresponding to Zn–N stretching vibrations and 733.79 and 763.11 cm−1 corresponding to Zn–O stretching vibrations.35 The IR spectrum of 2 showed bands at 612.25 and 582.50 cm−1 corresponding to Zn–N bonds and 412.77 cm−1 corresponding to the newly formed Zn–S bonds in 2. The IR spectrum of 3 exhibited a band at ∼416.77 cm−1 corresponding to the newly formed Zn–S bond and 601.79 cm−1 corresponding to the Zn–N bonds.35,36

Fig. 2 Job's plot for the L2-substituted product 3.

Fig. 3 FT-IR spectra of (a) 1, (b) L1-substituted product 2, and (c) L2-substituted product 3.

Fig. 4(a)–(c) show the ESI-MS spectra of 1, 2, and 3. The signals at 187.97, 279.93, 434.99, and 618.88 (Fig. 4(a)) correspond to [Zn2+ + 2bpy], [Zn2+ + 2bpy + OAc− + HClO4 + Na+], [Zn2+ + 2bpy + OAc−], and [Zn2+ + 2bpy + 2OAc− + HClO4 + Na+], respectively. The signals at 264.995 and 188.05 (Fig. 4(b)) are attributed to [Zn2+ + 2bpy + 2dl-penicillamine + H2O + ClO4− + 2H+] and [Zn2+ + 2bpy], respectively. The signals at 254.95 and 188.03 (Fig. 4(c)) correspond to [Zn2+ + 2bpy + 2l-cysteine + H2O + ClO4− + Na+] and [Zn2+ + 2bpy], respectively.

Fig. 4 ESI-MS spectrum of (a) 1, (b) L1-substituted product 2, and (c) L2-substituted product 3.

Kinetic studies

The pKa values for L1 are 1.90 (COOH), 7.88 (SH), and 10.58 (NH2) (Scheme 1),37 and those for L2 are 1.71 (COOH), 8.53 (SH), and 10.36 (NH2) (Scheme 2).38,39 These pKa values suggest that the S-containing ligands participate in the reactions in their anionic form (thiolate) at pH 7.4.

Scheme 1 The pKa values for L1.

Scheme 2 The pKa values for and L2.

The plot of ln(At − A∞) vs. t was non-linear; At and A∞ are absorbances at time t and after completion of the reaction, respectively (Fig. 5(a)). The plot curved initially before appearing linear with a constant slope. This indicates that the interactions of L1 and L2 with 1 proceed through two distinct steps (curved and linear). Scheme 3 was used to calculate the rate constants for both steps.

Fig. 5 (a) ln(At − A∞) vs. t and (b) ln Δ vs. t plots. [1] = 2 × 10−4 mol L−1, [ligand] = 4 × 10−3 mol L−1, pH = 7.4, and temperature = 35 ± 0.1 °C. X–Y = the difference between the absorbances of the two steps in the time interval.

Scheme 3 Interaction of complex 1 with L1 and L2 and product formation, where A, B, and C represent 1, intermediate product, and substituted product, respectively, and k1 and k2 are the rate constants for the first and second steps, respectively.

Calculation of k1 of step A → B

Weyh and Hamm's method40 was employed to calculate k1(obs) values from the typical plots of ln Δ vs. t without using Origin software, as the slope of the best-fitted line of the first part of the ln(A∞ − At) vs. t plot did not work for calculations shown in Fig. 5(a).5 (At − A∞) – a2 exp(−k2t) = a1 exp(−k1(obs)t)

where a1 and a2 are constants. The values of [(At − A∞) − a2 exp(−k2t)] were calculated from X–Y values at different time intervals (Fig. 6(a)) and denoted as the ‘Δ’ values.

Fig. 6 k 1(obs) vs. (a) [L1] and (b) [L2] at a fixed pH (7.4) and temperature (25 ± 0.1 °C).

Then, eqn (5) becomes6 ln Δ = constant − k1(obs)t

The k1(obs) was calculated from the slopes of ln Δ vs. t plots (Fig. 5(b)) at ligand concentrations of 2.0, 3.0, and 4.0 × 10−3 mol L−1 at fixed [1], pH 7.4, ionic strength of 0.1 mol L−1 NaClO4, and different temperatures (20, 25, 30, and 35 °C). Tables 1 and 2 present the k1(obs) data.

10−2k1(obs) values (s−1) for L1 at five different concentrations, four different temperatures, and constant pH (7.4), ionic strength (0.1 mol per L NaClO4), and [1] (2 × 10−4 mol L−1)

	System temperature (°C)	103 [ligand] mol L−1	
2.0	2.5	3.0	3.5	4.0	
L1	20	4.54	5.27	5.95	6.72	7.50	
25	4.73	5.57	6.40	7.53	8.65	
30	4.78	5.72	6.66	7.83	9.01	
35	5.00	6.05	7.12	8.37	9.63	

10−2k1(obs) values (s−1) for L2 at five different concentrations, four different temperatures, and constant pH (7.4), ionic strength (0.1 mol per L NaClO4), and [1] (2 × 10−4 mol L−1)

	System temperature (°C)	103 [ligand] mol L−1	
2.0	2.5	3.0	3.5	4.0	
L2	20	1.51	2.13	2.75	3.39	3.83	
25	2.63	2.94	3.24	3.65	4.05	
30	2.71	3.71	4.72	6.32	7.91	
35	5.06	7.03	9.00	10.4	11.8	

The plots of k1(obs)vs. [L] (Fig. 6(a) and (b)) are straight lines. The k1 values (slopes of the plots) at different [L] and temperatures (Tables 3 and 4) demonstrate that the rate increased as the [L] increased. The first step was ligand-dependent, which indicates that L1 or L2 attacks Zn(ii) to form intermediate B in this step (Scheme 3).

k 1 values of L1 at four different temperatures and constant pH (7.4), ionic strength (0.1 mol per L NaClO4), and [1] (2 × 10−4 mol L−1)

Ligand	Temperature (°C)	10−5k1 (L mol−1 s−1)	
L1	20	1.48 ± 0.02	
25	1.96 ± 0.08	
30	2.15 ± 0.07	
35	2.31 ± 0.06	

k 1 values of L2 at four different temperatures and constant pH (7.4), ionic strength (0.1 mol per L NaClO4), and [1] (2 × 10−4 mol L−1)

Ligand	Temperature (°C)	10−1k1 (L mol−1 s−1)	
L2	20	1.27 ± 0.017	
25	1.67 ± 0.05	
30	2.56 ± 0.31	
35	3.36 ± 0.32	

Calculation of k2 for step B → C

The k2(obs) values were calculated from the linear segment of ln(At − A∞) vs. t plot (Fig. 5(a) and Table 5). The plots of k2(obs)vs. [L] were also straight lines (Fig. 7(a) and (b)). The k2(obs) values increased with increasing [L] (Fig. 7 and Table 5). The k2 values (Table 6), which are the slopes of the plots at four temperatures (Fig. 7(a) and (b)), increased with increasing [L]. Therefore, the second step is ligand-dependent.

10−2k2(obs) values (s−1) of L1 and L2 at four different temperatures and three different concentrations and constant pH (7.4), ionic strength (0.1 mol per L NaClO4), and [1] (2 × 10−4 mol L−1)

	System temperature (°C)	103 [ligand] mol L−1	
2.0	2.5	3.0	3.5	4.0	
L1	20	2.51	5.15	6.62	10.25	12.73	
25	3.07	6.17	8.57	12.79	17.01	
30	3.75	8.13	12.50	15.95	21.11	
35	5.01	9.80	14.50	18.75	23.01	
L2	20	4.35	6.55	8.85	11.71	14.55	
25	5.00	7.45	10.10	13.35	16.64	
30	6.67	9.88	13.10	16.66	20.22	
35	7.40	10.90	14.50	18.05	22.50	

Fig. 7 Plot of k2(obs)vs. (a) [L1] and (b) [L2].

10−1k2 values of L1 and L2 at four temperatures and constant pH (7.4), ionic strength (0.1 mol per L NaClO4), and [1] (2 × 10−4 mol L−1)

Ligand	Temperature (°C)	10−1k2 (L mol−1 s−1)	
L1	20	5.10 ± 0.11	
25	6.96 ± 0.70	
30	8.67 ± 0.04	
35	9.00 ± 0.007	
L2	20	5.07 ± 0.33	
25	5.85 ± 0.43	
30	6.66 ± 0.13	
35	7.55 ± 0.25	

Effect of temperature on k1 and k2

Both k1 (Tables 3 and 4) and k2 (Table 6) increased with increasing operating temperatures. This suggests that the two substitution reactions are highly temperature-sensitive. Hence, their activation and thermodynamic parameters were evaluated using the Eyring equation. The Eyring plots (ln krh/kBT vs. 1/T) for the first and second steps of the reaction of L1 and 1 are shown in Fig. 8(a) and (b), whereas those of L2 are shown in Fig. 8(c) and (d). The enthalpy of activation values (ΔH≠1 and ΔH≠2) and the entropy of activation values (ΔS≠1 and ΔS≠2) are obtained from the slopes and the intercepts of the Eyring plots, respectively. The activation and thermodynamic parameters are listed in Table 7. The positive enthalpy and negative entropy values (Table 7) confirm the ligand dependency of 1 and the ligand interactions at each step.

Fig. 8 Eyring plots (a) ln k1h/kBT vs. 103/T for the A → B step of L1, (b) ln k2h/kBT vs. 103/T for the B → C step of L1, (c) ln k1h/kBT vs. 103/T for the A → B step of L2, and (d) k2h/kBT vs. 103/T for the B → C step of L2.

Activation and thermodynamic parameters for the reaction

Ligand	ΔH≠1 (kJ mol−1)	ΔS≠1 (J K−1 mol−1)	ΔH≠2 (kJ mol−1)	ΔS≠2 (J K−1 mol−1)	
L1	24.81 ± 0.54	−61 ± 1	26.76 ± 0.55	−120 ± 1	
L2	49.51 ± 2.33	−56 ± 2	18.09 ± 0.16	−150 ± 0.5	

Mechanism

The pKa values of L1 and L2 at 25 °C suggest that the S-containing ligands exist in their thiolate forms at pH 7.4. Job's method and FT-IR and ESI-MS spectra of 1, 2, and 3 confirm that L1 and L2 act as monodentate ligands, binding their S atoms to Zn, considering the predominant existence of ZnS in zinc ores.41

The highly negative S≠1 and ΔS≠2 and the less positive ΔH≠1 and ΔH≠2, determined from ln(At − A∞) vs. t plots (Fig. 5(a)), indicate an associative mode of activation with two distinct steps (Scheme 3). Moreover, the rate constants (k1 and k2) depended on the ligand concentration. This suggests that, in the first step, one molecule of L attacks the Zn(ii) to form intermediate B, which is further attacked by a second molecule of L to form the product.

The energy required for Zn–OAc bond cleavage is compensated by the energy released during Zn–L bond formation. The low ΔH≠1 and ΔH≠2 values support this inference. Our proposed mechanism is shown in Fig. 9.

Fig. 9 Plausible mechanism of the substitution reactions of 1 and L1/L2.

Bioassays

Electronic absorption titration

A metal complex can bind to the DNA double helix through intercalation42 or non-interactive modes, such as covalent, ionic, hydrophobic, and hydrogen bonds, as well as van der Waals interactions. The mode of interaction is reflected by (i) a change in absorption intensity (hyper or hypochromism) and (ii) a red or blue shift of the band.43

Fig. 10 shows the electronic absorption titration spectra of different ctDNA concentrations at a constant [1]. The absorption intensity decreased with increasing ctDNA concentrations without a red or blue shift (Fig. 10(a)). This hypochromism indicates an intercalative binding mode between 1 and ctDNA.44,45 The plot of [DNA]/(εb − εf) vs. [DNA] is linear (Fig. 10(b)). The Kb value (binding constant, 2.5 × 104 M−1) obtained from the slope of the plot indicates moderate to strong binding between 1 and ctDNA.

Fig. 10 (a) Electronic absorption spectra were obtained during the titration of 0.1 mM of 1 in Tris–HCl buffer with different [ctDNA] (0–20 μM). The arrow indicates a decrease in intensity upon the addition of ctDNA. (b) Linear fit of [DNA]/(εa − εf) vs. [DNA].

Fluorescence emission titration

An aqueous solution of 1 at room temperature and working pH did not fluoresce with or without DNA. The fluorescence intensity was too low for a solution of EtBr in Tris–HCl buffer (pH 7.4) in the absence of DNA. In contrast, the fluorescence intensity increased ∼20-fold in the presence of ctDNA, which suggests strong intercalation with the dye (EtBr).45,46 Therefore, a fluorescence quenching titration was performed to determine the binding nature of 1 and DNA.

Increasing the concentration of 1 decreased the emission intensity of the EtBr–DNA solution owing to successive quenching. This indicates competition between 1 and EtBr for ctDNA binding (Fig. 11(a)). The Ksv value of 1.5 × 103 M−1 was obtained using the Stern–Volmer plot, whereas KF (4.57 × 106 M−1) and n (1.4) values were obtained using Scatchard plots of 1 and ctDNA (Fig. 11(b) and (c)).

Fig. 11 (a) Fluorescence spectra at increasing [1] (10–100 μM) in an EtBr–DNA solution of pH 7.4 (Tris–HCl buffer); (b) Stern–Volmer plot and determination of Ksv; and (c) Scatchard plot of 1 and ctDNA and determination of KF and n.

Agarose gel electrophoresis

The nuclease activity of 1 was investigated using plasmid DNA (pBR322). The efficiency of the Zn(ii) complex in transforming the original form of DNA (closed circular supercoiled; form I) into a relaxed or nicked form (form II) or a linear form (form III) was evaluated.30 Complex 1 successfully cleaved plasmid DNA into different sizes in the absence of any precursors (e.g., UV light or reducing agent) at all concentrations (29, 50, 67, and 80 μM) (Fig. 12; lanes 1 to 4; untreated plasmid DNA was the control). All three forms of DNA were observed after digestion with 1. Moreover, DNA mobility from form-I to forms-II and III decreased, and the rate of digestion of plasmid DNA increased with increasing [1].47 Moreover, fainter bands (lanes 2–4) appeared at higher [1], confirming DNA degradation. Hence, the extent of DNA digestion is directly proportional to the initial [1]. The smear observed in the four lanes is attributed to EtBr, which strongly interacts with the complex.30

Fig. 12 Gel electrophoresis of plasmid DNA treated with 1.

Antimicrobial assay

The antimicrobial activity of 1 against fungal and bacterial strains was evaluated. The results of agar well diffusion are summarized in Table 8. A clear zone around the well (Fig. 13) confirmed that 1 inhibited the growth of Gram-positive and Gram-negative bacterial strains. This illustrates the bioactivity of a Zn(ii)–bpy complex.48 The activity increased with increasing [1]. In particular, 1 was more effective against Gram-positive bacteria (Fig. 13). This may be due to the different cell wall structures of Gram-positive and Gram-negative bacteria. Complex 1 was ineffective against Aspergillus niger and Gram-negative Enterobacter asburiae but was effective against Escherichia coli. In addition, lower to higher concentrations of bpy were effective against E. coli but not against S. aureus. Hence, this complex can be a new, cost-effective antimicrobial agent to combat microbes which are resistant to conventional antimicrobials. Sinha et al. reported that 2–10 mM ZnO significantly inhibited the growth of Gram-negative bacteria (Enterobacter sp.) but showed a minimal effect on Gram-positive bacteria (Bacillus subtilis), with an insignificant reduction in the viable bacterial count.49

Diameters of the inhibition zones (bearing a spectator ligand) of selected microbes at increasing [1]a

Microorganisms	Zone of inhibition (mm)	
bpy	L	M1	M2	H	H1	H2	H3	
Gram-negative bacteria	
Enterobacter asburiae	—	—	—	—	—	—	—	—	
Escherichia coli	10	11	12	12	13	14	14	15	
 	
Gram-positive bacteria	
Staphylococcus aureus	—	11	11	11	12	12	13	15	
Bacillus subtilis	<10	11	11	11	12	13	14	15	
Salinicoccus roseus	11	12	13	13	14	14	15	16	
Halomonas denitrificans	11	12	12	13	14	15	15	15	
 	
Fungus	
Aspergillus niger	—	—	—	—	—	—	—	—	
a [L] = 0.5 × 10−3 M; [M1] = 1.0 × 10−3 M; [M2] = 1.5 × 10−3 M; [H] = 2.0 × 10−3 M; [H1] = 2.5 × 10−3 M; [H2] = 3.0 × 10−3 M; and [H3] = 3.5 × 10−3 M.

Fig. 13 Effect of 1 on microbial growth estimated by inhibition zone (IZ).

We propose a mechanism for the antimicrobial activity of 1 based on the literature and our findings (Fig. 14).50 The charge density of Zn2+ is reduced to chelation in 1, which reduces its hydrophilicity and enhances lipophilicity. This enables its quick entry through the cell membrane (due to its lipidic nature).51,52 Then, 1 participates in bactericidal (killing) or bacteriostatic (blocking of active sites) mechanisms. An increase in Zn2+ concentration above the optimal limit disrupts ion homeostasis. This allows the efflux of Zn2+ inside the cell, causing a cytotoxic effect. Moreover, Zn2+ has been attributed to the upregulation of ROS, which leads to oxidative stress in bacterial cells. This is consistent with previous reports, which demonstrated that the antimicrobial properties of Zn-based complexes are correlated to ROS overproduction, which may be the underlying mechanism for cell death caused by DNA damage.50,53 The increased membrane permeability of bacterial cells, mediated by Zn2+, facilitates ion channel dysfunction. This disrupts respiratory processes and reduces energy-producing adenosine triphosphate synthesis.

Fig. 14 Plausible antimicrobial mechanism of 1.

Conclusions

A novel six-coordinate Zn(ii) complex was synthesized and characterized using electronic, FT-IR, and ESI-MS spectroscopy. Kinetic and mechanistic investigations were performed in an aqueous medium and under pseudo-first-order reaction conditions at physiological pH with two bio-relevant ligands bearing N, O, and S donor atoms. These substitution reactions involved two distinct ligand-dependent steps. Highly negative entropy of activation values and less positive enthalpy of activation values suggested an associative activation mode. The rate constants (k1) were in the following order: L1 (dl-penicillamine) ≫ L2 (l-cysteine). This was attributed to the lower pK2 value (SH) and +I effect of two methyl groups at the Cβ of L1. Even though both ligands have S and N donor sets, the ligands were bonded to Zn(ii) via their S end. In vitro, DNA-binding studies indicated a positive interaction between 1 ([Zn(bpy)2(OAc)2]) and ctDNA. We also demonstrated the bactericidal and fungicidal effects of 1 against selected microbial strains. This study can be summarized as follows: (i) selection of a non-toxic metal center (Zn(ii)); (ii) kinetic investigation to elucidate the selectivity and reactivity of different ligands; (iii) elucidation of DNA binding and cleavage capacity; and (iv) exploration of the antimicrobial activity of 1.

Data availability

Data supporting this study are openly available from Prof. Alak K. Ghosh.

Conflicts of interest

There are no conflicts to declare.

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT) (No. RS-2023-00219983). Moonis Ali Khan acknowledges financial support through the Researchers Supporting Project (RSP2024R345), King Saud University, Riyadh, Saudi Arabia. Another author (Dr R. Kumar) acknowledges support from the Creative and Challenging Research Program [grant number 2021R1I1A1A01060846] of the National Research Foundation (NRF) of the Republic of Korea.
==== Refs
References

Abdolmaleki S. Aliabadi A. Khaksar S. Coord. Chem. Rev. 2024 501 215579
Adhikari S. Nath P. Das A. Datta A. Baildya N. Duttaroy A. K. Pathak S. Biomed. Pharmacother. 2024 171 116211 38290253
Porchia M. Pellei M. Del Bello F. Santini C. Molecules 2020 25 5814 33317158
Ye R. Tan C. Chen B. Li R. Mao Z. Front. Chem. 2020 8 402 32509730
Soldatović T. V. Šmit B. Mrkalić E. M. Matić S. L. Jelić R. M. Serafinović M. Ć. Gligorijević N. Čavić M. Aranđelović S. Grgurić-Šipka S. J. Inorg. Biochem. 2023 240 112100 36535193
Singh S. Pal K. Int. J. Biol. Macromol. 2023 234 123602 36773860
Bhattacharyya S. Sarkar A. Dey S. K. Mukherjee A. J. Inorg. Biochem. 2014 140 131 142 25113858
Wang Z. Gai S. Wang C. Yang G. Zhong C. Dai Y. He F. Yang D. Yang P. Chem. Eng. J. 2019 361 117 128
Fakhar-e-Alam M. Amjad I. Saadullah M. Tahir M. Jawad M. Asif M. Atif M. Zara S. Rashad M. J. Saudi Chem. Soc. 2024 28 101814
Pearson R. G. J. Am. Chem. Soc. 1963 85 3533 3539
Gać P. Czerwińska K. Macek P. Jaremków A. Mazur G. Pawlas K. Poręba R. Environ. Toxicol. Pharmacol. 2021 82 103553 33238203
Devi C. B. Nandakishore T. Sangeeta N. Basar G. Devi N. O. Jamir S. Singh M. A. IOSR J. Dent. Med. Sci. 2014 13 18 23
Fraker P. J. King L. E. Laakko T. Vollmer T. L. J. Nutr. 2000 130 1399S 1406S 10801951
Chasapis C. T. Loutsidou A. C. Spiliopoulou C. A. Stefanidou M. E. Arch. Toxicol. 2012 86 521 534 22071549
Lansdown A. B. Mirastschijski U. Stubbs N. Scanlon E. Ågren M. S. Wound Repair Regen. 2007 15 2 16 17244314
Singh S. S. Jena B. Roy S. Nayak S. Behera S. K. Chakrabortty S. Tripathy S. K. Ali Khan M. Kumar R. Jeon B.-H. Stålsby Lundborg C. Mishra A. Chem. Eng. J. 2024 490 151788
MacDonald R. S. J. Nutr. 2000 130 1500S 1508S 10801966
Sardana K. Garg V. K. Dermatol. Ther. 2010 23 411 418 20666829
Qian J. Wang L. Gu W. Liu X. Tian J. Yan S. Dalton Trans. 2011 40 5617 5624 21468395
Zhang S. Q. Yu X. F. Zhang H. B. Peng N. Chen Z. X. Cheng Q. Zhang X. L. Cheng S. H. Zhang Y. Mol. Nutr. Food Res. 2018 62 e1700981 29457347
Pellei M. Del Bello F. Porchia M. Santini C. Coord. Chem. Rev. 2021 445 214088
Roguin L. P. Chiarante N. García Vior M. C. Marino J. Int. J. Biochem. Cell Biol. 2019 114 105575 31362060
Franich A. A. Živković M. D. Milovanović J. Arsenijević D. Arsenijević A. Milovanović M. Djuran M. I. Rajković S. J. Inorg. Biochem. 2020 210 111158 32622215
Huang C. Y. , in Methods in Enzymology, ed. D. L. Purich, Academic Press, 1982, vol. 87 , pp. 509–525
João J. P. M. Ann. Chim. Appl. 1928 113 203
Gao E. Liu L. Zhu M. Huang Y. Guan F. Gao X. Zhang M. Wang L. Zhang W. Sun Y. Inorg. Chem. 2011 50 4732 4741 21520903
Pal A. Biswas B. Mondal S. K. Lin C.-H. Ghosh R. Polyhedron 2012 31 671 675
Kanakis C. D. Tarantilis P. A. Polissiou M. Diamantoglou S. Tajmir-Riahi H. Cell Biochem. Biophys. 2007 49 29 36 17873337
El-Bindary A. A. Hassan N. El-Afify M. A. J. Mol. Liq. 2017 242 213 228
Mitra I. Mukherjee S. Reddy B V. P. Dasgupta S. Bose K J. C. Mukherjee S. Linert W. Moi S. C. RSC Adv. 2016 6 76600 76613
Borst P. IUBMB Life 2005 57 745 747 16511967
Balouiri M. Sadiki M. Ibnsouda S. K. J. Pharm. Anal. 2016 6 71 79 29403965
Geetha R. Sathian C. Prasad V. Gleeja V. Asian J. Dairy Food Res. 2015 34 259 264
Ristivojević P. Dimkić I. Trifković J. Berić T. Vovk I. Milojković-Opsenica D. Stanković S. PLoS One 2016 11 e0157097 27272728
Huang D. Xin Q. Ni Y. Shuai Y. Wang S. Li Y. Ye H. Lin L. Ding X. Zhang Y. RSC Adv. 2018 8 6099 6109 35539600
Liu L.-N. Dai J.-G. Zhao T.-J. Guo S.-Y. Hou D.-S. Zhang P. Shang J. Wang S. Han S. RSC Adv. 2017 7 35075 35085
Martell A. E. and Smith R. M. , Critical Stability Constants, Springer, 1974
Hager G. Brolo A. G. J. Electroanal. Chem. 2009 625 109 116
Dourado A. H. de Lima Batista A. P. Oliveira-Filho A. G. Sumodjo P. T. de Torresi S. I. C. RSC Adv. 2017 7 7492 7501
Weyh J. A. Hamm R. E. Inorg. Chem. 1969 8 2298 2302
Cotton F. A. , Wilkinson G. , Murillo C. A. and Bochmann M. , Advances in Inorganic Chemistry, John Wiley & Sons, 1999
Zeglis B. M. Pierre V. C. Barton J. K. Chem. Commun. 2007 4565 4579 10.1039/B710949K
Arjmand F. Aziz M. Chauhan M. J. Inclusion Phenom. Macrocyclic Chem. 2008 61 265 278
Brabha M. J. Malbi M. A. Chem. Phys. Impact 2023 7 100248
Arjmand F. Chauhan M. B. Helv. Chim. Acta 2005 88 2413 2423
Zhang C.-L. Cai D.-H. Chen S. Liu W. Xiong Y.-H. Le X.-Y. Transition Met. Chem. 2019 44 603 613
Zhang Q. Xiang Y. Liang D. Peng Y. Guo H. Bioorg. Med. Chem. Lett. 2012 22 1814 1817 22257891
Santoso S. P. Ismadji S. Angkawijaya A. E. Soetaredjo F. E. Go A. W. Ju Y. H. J. Mol. Liq. 2016 221 617 623
Sinha R. Karan R. Sinha A. Khare S. K. Bioresour. Technol. 2011 102 1516 1520 20797851
Matai I. Sachdev A. Dubey P. Uday Kumar S. Bhushan B. Gopinath P. Colloids Surf., B 2014 115 359 367
Pranjal Chandra Mahapatra G. Chakrabortty S. Banerjee S. Chowdhury S. Ali Khan M. Kumar R. Jeon B.-H. Mishra A. Stålsby Lundborg C. Tripathy S. K. Chem. Eng. J. 2024 497 154670
Jena B. Singh S. S. Chakrabortty S. Behera S. K. Tripathy S. K. Lundborg C. S. Kumar R. Ali Khan M. Jeon B. H. Mishra A. J. Ind. Eng. Chem. 2024 10.1016/j.jiec.2024.04.049
Wang F.-Y. Xi Q.-Y. Huang K.-B. Tang X.-M. Chen Z.-F. Liu Y.-C. Liang H. J. Inorg. Biochem. 2017 169 23 31 28095346
